Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$40 Mln
Revenue (TTM)
$437 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.7 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0.9
Industry P/E
44.78
EV/EBITDA
26.3
Div. Yield
0 %
Debt to Equity
2.3
Book Value
$--
EPS
$-0.3
Face value
--
Shares outstanding
118,782,630
CFO
$55.64 Mln
EBITDA
$80.07 Mln
Net Profit
$-188.18 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Accuray (ARAY)
| -49.6 | -28.1 | -49.6 | -76.7 | -48.1 | -39.1 | -23.1 |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Accuray (ARAY)
| -58.4 | -29.8 | 35.4 | -56.2 | 14.4 | 47.9 | -17.3 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Accuray (ARAY)
|
0.4 | 40.4 | 437.0 | -35.6 | -2.4 | -52.9 | -- | 0.9 |
| 7.9 | 5,388.2 | 6,552.2 | -530.2 | -4.1 | -9.2 | -- | 0.9 | |
| 278.3 | 7,510.1 | 2,583.2 | 759.9 | 25.2 | 10.8 | 10 | 1.0 | |
| 36.8 | 5,222.6 | 3,436.5 | -8.6 | 2.2 | -0.4 | -- | 2.1 | |
| 112.8 | 6,549.6 | 507.4 | -187.7 | -36.2 | -26.4 | -- | 10.0 | |
| 76.1 | 4,758.4 | 1,541.6 | 233.6 | 21.6 | 21.4 | 21.4 | 4.5 | |
| 178.6 | 9,411.8 | 1,526.9 | -151.5 | 20.0 | -17.1 | -- | 12.9 | |
| 330.4 | 12,964.3 | 1,403.7 | 177.7 | 14.7 | 13.8 | 72.9 | 9.0 | |
| 117.8 | 6,280.4 | 738.3 | 48.9 | 11.4 | 2.4 | 129.6 | 3.0 | |
| 32.1 | 13,716.9 | 6,178.4 | 626.5 | 13.0 | 11.9 | 22.5 | 2.6 |
Accuray Incorporated engages in the design, development, manufacture, and sale of radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle... East, India, Africa, Japan, and China. The company offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. It also provides the TomoTherapy platform, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, the company offers post-contract customer support, installation, training, and other professional services. It primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin. Address: 1240 Deming Way, Madison, WI, United States, 53717-1954 Read more
President, CEO & Director
Ms. Suzanne Winter M.B.A.
President, CEO & Director
Ms. Suzanne Winter M.B.A.
Headquarters
Madison, WI
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Accuray Incorporated (ARAY) is $0.42 (NASDAQ) as of 02-Apr-2026 19:29 EDT. Accuray Incorporated (ARAY) has given a return of -48.1% in the last 3 years.
Since, TTM earnings of Accuray Incorporated (ARAY) is negative, P/E ratio is not available.
The P/B ratio of Accuray Incorporated (ARAY) is 0.87 times as on 31-Mar-2026, a 71 discount to its peers’ median range of 2.95 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-93.77
|
1.84
|
|
2024
|
-11.83
|
4.08
|
|
2023
|
-40.01
|
6.92
|
|
2022
|
-34.11
|
3.43
|
|
2021
|
-65.61
|
6.02
|
The 52-week high and low of Accuray Incorporated (ARAY) are Rs 2.10 and Rs 0.33 as of 05-Apr-2026.
Accuray Incorporated (ARAY) has a market capitalisation of $ 40 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Accuray Incorporated (ARAY), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.03
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.